Drugs / GB201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03721744 | Oct 2018 → Mar 2025 | malignant pancreatic neoplasm | 1Globe Health Institute LLC | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03721744 ↗ |
| Route | Oral | “administered orally” NCT03721744 ↗ |